Spots Global Cancer Trial Database for refractory primary central nervous system neoplasm

Every month we try and update this database with for refractory primary central nervous system neoplasm cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors	NCT02867592	Adrenal Cortica... Alveolar Soft P... Central Nervous... Childhood Clear... Clear Cell Sarc... Ewing Sarcoma Hepatoblastoma Hepatocellular ... Osteosarcoma Recurrent Adren... Recurrent Alveo... Recurrent Clear... Recurrent Ewing... Recurrent Hepat... Recurrent Hepat... Recurrent Kidne... Recurrent Malig... Recurrent Osteo... Recurrent Prima... Recurrent Renal... Recurrent Rhabd... Recurrent Soft ... Recurrent Thyro... Refractory Adre... Refractory Alve... Refractory Clea... Refractory Ewin... Refractory Hepa... Refractory Hepa... Refractory Mali... Refractory Oste... Refractory Prim... Refractory Prim... Refractory Rena... Refractory Rhab... Refractory Soft... Refractory Thyr... Refractory Wilm... Renal Cell Carc... Rhabdomyosarcom... Soft Tissue Sar... Solid Neoplasm Thyroid Gland M... Wilms Tumor	Cabozantinib Cabozantinib S-... Pharmacological...	2 Years - 30 Years	National Cancer Institute (NCI)
Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02975882	Childhood Solid... Recurrent Malig... Recurrent Prima... Refractory Mali... Refractory Prim...	Irinotecan Hydr... Laboratory Biom... Pharmacological... Sirolimus Album... Temozolomide	12 Months - 21 Years	Children's Oncology Group
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	NCT03598244	Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging	6 Years - 21 Years	National Cancer Institute (NCI)
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors	NCT02415153	Neurofibromatos... Recurrent Child... Recurrent Child... Recurrent Prima... Refractory Prim...	Laboratory Biom... Pharmacological... Pomalidomide	3 Years - 20 Years	National Cancer Institute (NCI)
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)	NCT03213678	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Malignant Gliom... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biospecimen Col... Computed Tomogr... FDG-Positron Em... Magnetic Resona... Samotolisib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)	NCT03220035	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Ependymoma Ewing Sarcoma Hepatoblastoma Langerhans Cell... Malignant Germ ... Malignant Gliom... Osteosarcoma Peripheral Prim... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim... Rhabdoid Tumor Rhabdomyosarcom... Soft Tissue Sar... Wilms Tumor	Laboratory Biom... Vemurafenib	12 Months - 21 Years	National Cancer Institute (NCI)
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study	NCT04500548	Constitutional ... Hematopoietic a... Lynch Syndrome Recurrent Lymph... Recurrent Malig... Recurrent Neuro... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Neur... Refractory Prim... Xeroderma Pigme...	Biospecimen Col... Ipilimumab Nivolumab	12 Months - 25 Years	National Cancer Institute (NCI)
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)	NCT03213691	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Recurrent Child... Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Mali... Refractory Neur... Refractory Non-... Refractory Prim...	Laboratory Biom... Selumetinib Selumetinib Sul...	12 Months - 21 Years	National Cancer Institute (NCI)
Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma	NCT03323034	Recurrent Lymph... Recurrent Malig... Recurrent Prima... Refractory Lymp... Refractory Mali... Refractory Prim...	Irinotecan Pevonedistat Temozolomide	6 Months - 21 Years	Children's Oncology Group
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors	NCT01709435	Recurrent Malig... Recurrent Melan... Recurrent Prima... Recurrent Thyro... Refractory Mali... Refractory Prim... Thyroid Gland M...	Cabozantinib S-... Laboratory Biom... Pharmacological...	2 Years - 18 Years	National Cancer Institute (NCI)
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas	NCT02323880	Malignant Gliom... Recurrent Brain... Recurrent Child... Recurrent Child... Recurrent Lymph... Recurrent Malig... Refractory Lymp... Refractory Mali... Refractory Prim... WHO Grade 3 Gli...	Pharmacological... Selinexor	12 Months - 21 Years	Children's Oncology Group
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors	NCT03598244	Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	Biospecimen Col... Magnetic Resona... Savolitinib X-Ray Imaging	6 Years - 21 Years	National Cancer Institute (NCI)
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors	NCT02780804	Brain Stem Neop... Pineal Region N... Recurrent Lymph... Recurrent Malig... Recurrent Prima... Recurrent Visua... Refractory Lymp... Refractory Mali... Refractory Prim... Refractory Visu...	Entinostat Laboratory Biom... Pharmacological...	12 Months - 21 Years	National Cancer Institute (NCI)
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors	NCT05278208	High Grade Glio... Meningioma Embryonal Tumor Medulloblastoma Anaplastic Epen... Recurrent Diffu... Recurrent Malig... Recurrent Medul... Recurrent Prima... Refractory Diff... Refractory Mali... Refractory Medu... Refractory Prim...	LUTATHERA® (Lut...	4 Years -	Nationwide Children's Hospital
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)	NCT03155620	Advanced Malign... Ann Arbor Stage... Ann Arbor Stage... Histiocytic Sar... Juvenile Xantho... Langerhans Cell... Malignant Gliom... Recurrent Child... Recurrent Epend... Recurrent Ewing... Recurrent Gliom... Recurrent Hepat... Recurrent Lange... Recurrent Malig... Recurrent Malig... Recurrent Medul... Recurrent Neuro... Recurrent Non-H... Recurrent Osteo... Recurrent Perip... Recurrent Prima... Recurrent Rhabd... Recurrent Soft ... Refractory Ewin... Refractory Glio... Refractory Hepa... Refractory Lang... Refractory Mali... Refractory Mali... Refractory Medu... Refractory Neur... Refractory Non-... Refractory Oste... Refractory Peri... Refractory Prim... Refractory Rhab... Refractory Rhab... Rhabdoid Tumor Stage III Osteo... Stage III Soft ... Stage IV Osteos... Stage IV Soft T... Stage IVA Osteo... Stage IVB Osteo... Wilms Tumor	Biopsy Biospecimen Col... Bone Marrow Asp... Bone Scan Computed Tomogr... Ensartinib Erdafitinib Laboratory Biom... Larotrectinib S... Magnetic Resona... Mutation Carrie... Olaparib Palbociclib Pharmacological... Positron Emissi... Radionuclide Im... Samotolisib Selpercatinib Selumetinib Sul... Tazemetostat Tipifarnib Ulixertinib Vemurafenib X-Ray Imaging	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: